Dr. Reddy’s Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine. This partnership aims to make the vaccine available in India’s private market for pediatric and adult vaccination starting in the first half of 2027. The agreement leverages Dr. Reddy’s extensive network and Takeda’s vaccine expertise to address India’s growing dengue burden.
Exclusive Distribution Agreement for Qdenga®
Dr. Reddy’s Laboratories Ltd. announced on September 18, 2026, that it has signed an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited (Takeda) for the dengue vaccine, Qdenga®. This strategic partnership focuses on the private market in India, targeting both pediatric and adult vaccinations.
Market Entry and Availability
Qdenga® is India’s first CDSCO-approved dengue vaccine, developed by Takeda to protect against all four dengue virus serotypes. The vaccine is anticipated to become available in the private market in the first half of 2027, following the completion of applicable processes with local authorities. This collaboration aims to address the significant and growing public health challenge posed by dengue in India.
Roles and Responsibilities
Under the terms of the agreement, Dr. Reddy’s will be responsible for the distribution and marketing of Qdenga® in the private sector. Takeda, while retaining commercialization rights for the public market in India, will oversee the manufacturing and importation of the vaccine. This division of responsibilities leverages each company’s strengths, with Dr. Reddy’s contributing its extensive healthcare network and commercial reach across India, and Takeda bringing its global expertise in dengue prevention and vaccine science.
Strategic Alignment and Rationale
This partnership is aligned with Dr. Reddy’s strategy to bolster its vaccines business in India and contribute to broader public health efforts. Dengue cases in India have increased significantly over the past two decades, making prevention and management an urgent priority. The collaboration is expected to amplify impact by combining Takeda’s vaccine development capabilities and Dr. Reddy’s established market presence.
Agreement Details
The agreement does not involve any upfront consideration or milestone payments, with other commercial terms remaining confidential. Neither Dr. Reddy’s nor Takeda is acquiring the other. Takeda is not considered a related party to Dr. Reddy’s or its promoter group.
Source: BSE
